#Israel #Amorphical #Nes Ziona #AMOR-1 #hypoparathyroidism

Amorphical Completes Patient Enrollment in Phase 2 Clinical Trial

Amorphical, an innovative biotechnology company, has achieved a significant milestone by completing patient enrollment in a pivotal Phase 2 clinical trial evaluating its new therapeutic candidate, AMOR-1. This investigational therapy is designed for adults suffering from hypoparathyroidism, a rare endocrine disorder characterized by an insufficient parathyroid hormone, leading to dangerously low levels of calcium in the blood.

Background on Hypoparathyroidism

Hypoparathyroidism is a rare condition that affects how the body regulates calcium levels. The current standard treatment involves long-term, high-dose daily crystalline calcium supplementation along with active vitamin D. Unfortunately, prolonged use of high-dose calcium supplements can lead to serious side effects, including renal calcification and kidney stones. Additionally, many patients have to combine these supplements with high-cost synthetic hormone replacement therapies, which also come with their own risks.

AMOR-1 and its Advantages

AMOR-1 leverages Amorphical's proprietary nano-amorphous calcium carbonate technology (ACC), which is designed to enhance calcium absorption and bioavailability when compared to standard crystalline forms. This innovative approach allows patients to maintain optimal serum calcium levels while significantly reducing their overall intake of elemental calcium. The hope is that AMOR-1 can address the serious disadvantages of current treatment protocols.

Phase 2 Trial Details

The Phase 2 clinical trial is a double-blind, randomized study with multiple international sites. It includes 50 adult participants who are being divided into two groups. One cohort will receive AMOR-1, while the control group will continue with their existing calcium carbonate supplements. The initial phase will involve a gradual substitution of baseline supplements over 2 to 4 weeks, allowing a calculated 50% reduction in total calcium intake for those on AMOR-1. Patients will then undergo a maintenance phase lasting 10 to 12 weeks, during which their safety and efficacy will be meticulously monitored using blood and urine tests.

Expert Insights

Professor Ilan Shimon, the study's lead investigator and Director of the Institute of Endocrinology and Metabolism at Beilinson Hospital, emphasizes the importance of AMOR-1 in achieving a delicate balance for hypoparathyroidism patients. He states, “The ability of AMOR-1's nano-amorphous platform to deliver highly bioavailable calcium means we may finally be able to maintain desired serum calcium levels with half the elemental calcium compared to conventional therapies.” These statements highlight the potential impact of the trial results on patient care and treatment protocols.

Future Directions

The completion of patient enrollment is a crucial step for Amorphical as it moves toward its goal of redefining hypoparathyroidism care. The company is eager to examine the unblinded data in the coming months, which will assist in progressing their regulatory timeline and evolving strategic commercialization pathways. In addition to its efforts in treating hypoparathyroidism, Amorphical is engaged in advancing clinical programs targeting pancreatic cancer, Crohn's disease, and osteoporotic fractures, showcasing its commitment to addressing significant unmet medical needs.

Conclusion

With its novel technology and strategic clinical focus, Amorphical aims to provide safer, more effective treatment options for patients with hypoparathyroidism. The biomedicine sector is eagerly awaiting the trial results, which could signal a meaningful change in standard care approaches for this challenging condition. As Amorphical continues to innovate and develop, its role in the field of biotechnology is becoming increasingly visible and impactful.

To learn more about Amorphical and its innovative therapies, visit amorphical.com.